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Abstract
Background: The prevalence of the metabolic syndrome (MS) has been determined in many countries worldwide
but never in Luxembourg. This research aimed to 1) establish the gender- and age-specific prevalence of MS and
its components in the general adult population of Luxembourg, according to the most recent Joint Interim
Statement (JIS) definition, by using both the high and low cut-off points to define abdominal obesity, and 2)
compare and assess the degree of agreement with the Revised National Cholesterol Education Programme-Adult
Treatment Panel III (R-ATPIII) and the International Diabetes Federation (IDF) definitions.
Methods: A representative stratified random sample of 1349 European subjects, aged 18-69 years, participated to
ORISCAV-LUX survey. Logistic regression and odds ratios (OR) were used to study MS prevalence with respect to
gender and age. The Framingham risk score (FRS) to predict the 10-year coronary heart disease (CHD) risk was
calculated to compare the proportion of MS cases below or above 20%, according to both high and low waist
circumference (WC) thresholds. Cohen’s kappa coefficient () was utilized to measure the degree of agreement
between MS definitions.
Results: The prevalence of the MS defined by the JIS was 28.0% and 24.7% when using the low (94/80) and the
high (102/88) WC cut-off points, respectively. The prevalence was significantly higher in men than in women (OR =
2.6 and 2.3 for the low and high WC thresholds), as were all components of the MS except abdominal obesity
measured by both thresholds. It also increased with age (OR values in age categories ranging from 2.7 to 28 when
compared to the younger subjects for low WC and from 3.3 to 31 for the high WC cut-offs). The 10-year predicted
risk of CHD by FRS did not depend on the threshold used. Globally, excellent agreement was observed between
the three definitions of MS (= 0.89), in particular between JIS and IDF ( = 0.93). Agreement was significantly
higher in women than in men, and differed between age groups.
Conclusion: Regardless of the definition used, the adult population of Luxembourg reveals a high MS prevalence.
Our findings contribute to build evidence regarding the definitive construct of the MS, to help selecting the waist
circumference thresholds for Europid populations, and to support the need to revise the guidelines for abdominal
obesity levels.
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The metabolic syndrome (MS) consists of a cluster of
several metabolic and physiological abnormalities, includ-
ing obesity, impaired glucose regulation, dyslipidemia and
hypertension. It has become a subject of paramount
interest in both research and clinical medicine, owing to
its association with the increased risk of developing type
2 diabetes and atherosclerotic cardiovascular disease
(CVD) [1-6]. During the last ten years, several working
definitions have been proposed by various American,
European and International organizations [7-12].
The multiplicity of definitions had an impact on the
estimated MS prevalence rates in different populations
and complicated the interpretation of epidemiological
study results [13]. Several studies compared the concor-
dance between the MS definitions which yielded a mix-
ture of viewpoints regarding the most appropriate
criteria [14], [15].
In addition, the recent guidelines released by the Joint
Interim Statement (JIS) 2009[16] stressed the need to
adopt ethnic-specific values of waist circumference (WC),
to measure the central obesity criterion. For a given WC,
Asians, Blacks, Caucasians showed different levels of
intra-abdominal adiposity, hence putting the subjects at
different risk levels of CVD and diabetes[17], [18].
So far, there is no agreement between the organiza-
tions, on the WC threshold to define abdominal obesity
in people of European origin (Europid). While the IDF
recommended a WC ≥ 94 cm for men and ≥ 80 cm for
women, the European Cardiovascular Societies preferred
cut points of ≥102 cm and ≥ 88 cm, respectively, for the
two genders. Meanwhile, the JIS suggested using
national or regional cut-off points for WC until more
evidence from research work become available.
Despite the diversity of definitions, the prevalence of
MS is well-known in various populations worldwide[19].
So far, however, there is no such information available
in Grand-Duchy of Luxembourg. This work purposed
f o rt h ef i r s tt i m et o1 )e s t a b l i s ht h eg e n d e r -a n da g e -
specific prevalence of MS and its components in the
European adults residing in Luxembourg, according to
the most recent JIS definition by using both the high
and low WC cut-off values, and 2) compare the concor-
dance with other operating definitions sharing substan-
tially the same criteria (R-ATPIII and IDF).
Methods
Study population
A population-based, cross-sectional survey of cardiovas-
cular risk factors (ORISCAV-LUX) was conducted in
2007-2008 in Grand-Duchy of Luxembourg. A represen-
tative random sample of 4496 non-institutionalized sub-
jects residing in Luxembourg stratified according to
gender, age (5-year categories) and geographic district
(Luxembourg, Diekirch and Grevenmacher) was drawn
from the regularly updated national health insurance
registry. The distribution of selected subjects in each
stratum was proportional to their distribution in the tar-
get population. A total of 1432 subjects took part in the
survey, yielding a participation rate of 32.2%. A compre-
hensive description of the ORISCAV-LUX survey
design, sampling method, and sample representativeness
was published elsewhere [20], [21]. Briefly, selected per-
sons were invited through an official letter followed by a
phone contact to confirm the appointment. The partici-
pants were requested to keep at least 8 h fasting at
attendance. The trained research nurses either visited
participants in their households or invited them to the
nearest study investigation centre. At the time of inter-
view, the participants initially signed the informed con-
sent form and then filled in the auto-administered
questionnaire with the help of research staff. Given the
multi-linguistic nature of the population residing in
Luxembourg, the self-administered questionnaire was
translated from French into the three other most used
languages, namely German, English and Portuguese, and
then backward translated into French to ensure the
validity [22]. Information about past medical history,
family history, demographic characteristics, socioeco-
nomic status, physical activity, smoking, drinking and
alimentary habits were collected. Subjects on regular
medication were asked to bring their medicaments at
attendance. The auto-administered questionnaires were
chosen after careful review of the internationally avail-
able, tested and validated questionnaires on similar epi-
demiological studies.
Anthropometric measurements including height, body
weight, as well as hip and WC, were conducted with the
foot bare subjects wearing light clothing, by trained
research nurses, according to a standardized operating
procedure. Body weight (kg) was measured to the near-
est 0.1 kg with electronic medical scales (Seca,
Germany). Standing body height (cm) was measured to
the nearest 0.2 cm with a portable wall stadiometer
(Seca, Germany). Waist circumference (WC, cm) was
measured at the level midway between 12
th rib and the
uppermost lateral border of the iliac crest during mild
expiration. WC was measured to the nearest 0.2 cm in
standing position, using a flexible, non-distensible tape
without exertion of pressure on the tissues. The body
mass index (BMI) was calculated as weight divided by
height squared (kg/m
2).
Three consecutive measurements of sitting blood pres-
sure at minimum 5-min interval were recorded, by using
Omrom
® MX3 plus automated oscillometric Blood
Pressure Monitor (O-HEM-742-E) (Matsusaka, Japan)
[23], after the participants had been sitting for at least
30 minutes and refrained from smoking before the
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Page 2 of 9measurements. Systolic blood pressure (SBP, mmHg)
and diastolic blood pressure (DBP, mmHg) were com-
puted as the mean of the three measurements.
In addition, blood samples were collected from the
antecubital vein to measure fasting plasma glucose (FPG,
mg/dl), triglycerides (TG, mg/dl)), total cholesterol (TC,
mg/dl), low-density lipoprotein cholesterol (LDL-C,
mg/dl), high-density lipoprotein cholesterol (HDL-C, mg/
dl), by using Roche (Switzerland) reagents on a P module
of a Modular analyzer (Roche, Switzerland). All biochem-
ical analyses were carried out within 2 h of blood sam-
pling in the core laboratory of “Centre Hospitalier du
Luxembourg (CHL)”. The CHL laboratory applies strict
internal and external standard quality control techniques.
Definitions of metabolic syndrome
The last three operating definitions of MS were used.
Participants were identified as having R-ATPIII MS[12]
if they had three or more of the following criteria:
1) WC ≥ 102 cm for men and ≥ 88 cm for women;
2) raised concentration of TG ≥ 150 mg/dl or specific
treatment for this lipid anomaly; 3) reduced concentra-
tion of HDL-C < 40 mg/dl for men and < 50 mg/dl for
women or specific treatment for this lipid anomaly;
4) SBP was ≥ 130 mmHg, or DBP ≥ 85 mmHg or treat-
ment of previously diagnosed hypertension; 5) FPG level
≥100 mg/dl or use of medication for hyperglycemia.
The IDF definition[8] requires central obesity as a pre-
requisite (WC ≥ 94 cm for men and ≥ 80 cm for
women) plus two or more of the same remaining four
criteria (raised concentration of TG, reduced concentra-
tion of HDL-C, elevated blood pressure and FPG level).
Participants who self-reported a clinical diagnosis of dia-
betes by answering yes to the question “Did a doctor
inform you that you have diabetes?”, were considered as
having this feature in the IDF-MS definition.
The JIS 2009 definition requires the presence of 3 out
of the 5 above mentioned components to establish the
diagnosis of MS. The dual references for Europid-speci-
fic WC cut-off points to define the abdominal obesity
were applied; (1) WC ≥ 94 cm for men and ≥ 80 cm for
women, as suggested by the IDF, and (2) WC ≥ 102 cm
for men and ≥ 88 cm for women, as suggested by
European Societies of cardiology. However, by applying
the 102/88 thresholds, the definition criteria were
exactly consistent with the R-ATPIII definition.
Framingham risk score calculation
For every participant, the Framingham risk score (FRS)
to predict 10-year coronary heart disease (CHD) risk
was calculated using the adapted simplified model of
Wilson et al [24], including the weighted risk factors:
age, gender, blood pressure, LDL-C, HDL-C, smoking,
and diabetes mellitus.
Ethics
All participants were duly informed and consented to
take part in the ORISCAV-LUX survey. The study
design and collected data were approved by the National
Research Ethics Committee and the National Commis-
sion for Private data Protection.
Statistical analysis
Results were expressed as counts and proportions (%)
for categorical variables. The overall prevalence of MS
and of its individual components was estimated from
the data and was associated with its 95% confidence
interval (95%CI). Logistic regression analysis was applied
to test the potential effect of age, gender and age-gender
interaction on MS prevalence. Results were expressed in
terms of the odds ratio (OR) together with its 95%CI.
To account for the stratified random sampling
method, weighted statistical methods were applied.
A sampling weight equal to the inverse probability of
unit selection was allocated to each subject from the
same stratum. This stratum sampling weight was
defined as the ratio between the population stratum size
and the observed sample stratum size.
The FRS was calculated for each individual and subse-
quently dichotomized to compare the proportion of MS
cases with predicted 10-year risk of CHD below
or above 20%, according to the two WC thresholds
envisaged.
The percentage of subjects classified as MS was calcu-
lated for each pair of definitions as well as for the three
definitions together. Finally, to measure the degree of
agreement between MS definitions, Cohen’s kappa coef-
ficient () was utilized: the closer  to 1, the better the
agreement between the definitions.
Results were considered to be significant at the 5% cri-
tical level (P < 0.05). All statistical analyses were per-
formed by using the SAS 9.2 survey procedure for
complex sampling design (© SAS Institute Inc., Cary,
NC, USA).
Results
JIS definition based on higher and lower WC thresholds
A total of 1432 subjects participated in the ORISCAV-
LUX survey. However, after eliminating the non-
European residents and those with missing data on MS
components, only 1349 participants were available for
analysis.
Table 1 illustrates the JIS prevalence of MS and its
components by using the two suggested WC cut-off
values (102/88 and 94/80) among adult residents of Lux-
embourg. By applying the low thresholds, the MS preva-
lence was 28.0% as compared to 24.7% for the high
thresholds. The prevalence of 102/88-based abdominal
obesity criterion was markedly lower (30.6%) than that
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Page 3 of 9Table 1 JIS-prevalence of the metabolic syndrome and of its components by using both high and low WC cut-off values (102/88 and 94/80) respectively
among adults aged 18-69 years in the ORISCAV-LUX study
n JIS-94/80*
(n = 1320)
JIS-102/88†
(n = 1319)
Abdominal obesity
102/88 cut-off
(n = 1348)
Abdominal obesity
94/80 cut-off
(n = 1348)
Raised TG
(n = 1320)
Low HDL-C
(n = 1320)
High BP
(n = 1348)
Hyperglycaemia
(n = 1317)
Total 1349 28.0
(25.9 - 30.2)
24.7
(22.7 - 26.8)
30.6
(28.4 - 33.0)
51.7
(49.2 - 54.1)
25.6
(23.5 - 27.9)
18.8
(16.8 - 20.9)
52.5
(50.1 - 54.8)
21.7
(19.7 - 23.7)
Gender
Women 692 20.4
(17.9 - 23.2)
18.5
(16.1 - 21.2)
35.1
(31.8 - 38.4)
57.7
(54.2 - 61.2)
14.7
(12.4 - 17.4)
16.2
(13.7 - 19.1)
42.2
(39.1 - 45.4)
14.4
(12.1 - 16.7)
Men 657 35.5
(32.2 - 38.9)
30.8
(27.6 - 34.0)
26.3
(23.3 - 29.6)
45.7
(42.2 - 49.2)
36.5
(33.0 - 40.2)
21.3
(18.5 - 24.6)
62.5
(59.0 - 65.9)
29
(25.8 - 32.2)
P-value < 0.0001 < 0.0001 0.0002 < 0.0001 < 0.0001 0.014 < 0.0001 < 0.0001
Age (years)
Women
18-29 108 1.90
(0.5 - 7.4)
0.90
(0.1 - 6.4)
11.2
(6.5 - 18.6)
30.1
(22.6 - 38.9)
4.2
(1.6 - 10.2)
6.9
(3.3 - 14.0)
11.1
(6.3 - 18.7)
0.00 (-)
30-39 165 9.6
(5.8 - 15.5)
7.8
(4.5 - 13.1)
30.2
(23.6 - 37.8)
56.1
(48.0 - 63.8)
8.8
(5.3 - 14.4)
9.5
(5.7 - 15.5)
27.0
(20.4 - 34.7)
5.2
(2.7 - 9.9)
40-49 175 18.6
(13.4 - 25.2)
16.3
(11.4 - 22.6)
34.5
(27.6 - 42.1)
58.0
(50.4 - 65.2)
10.0
(6.2 - 15.7)
13.8
(9.2 - 20.2)
42.6
(35.6 - 49.8)
18.3
(13.2 - 24.9)
50-59 140 37.8
(30.2 - 46.2)
34.2
(26.8 - 42.4)
48.2
(40.3 - 56.2)
71.3
(63.4 - 78.1)
20.2
(14.3 - 27.7)
20.3
(14.3 - 28.1)
66.7
(58.6 - 73.9)
31.0
(24.0 - 39.0)
60-69 104 50.8
(41.0 - 60.6)
49.8
(40.0 - 59.7)
66.7
(57.4 - 75.8)
88.0
(80.2 - 92.9)
42.6
(32.2 - 52.6)
41.8
(32.5 - 51.7)
89.0
(80.6 - 94.0)
27.5
(19.8 - 36.7)
P-value < 0.0001 < .0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
Men
18-29 98 9.5
(5.1 - 17.1)
7.5
(3.6 - 15.0)
8.1
(4.1 - 15.4)
15.9
(10.2 - 23.9)
15.1
(9.1 - 24.2)
10.9
(5.8 - 19.6)
36.0
(27.5 - 45.6)
9.5
(5.0 - 17.4)
30-39 156 18.2
(12.9 - 25.1)
17.1
(12.0 - 23.9)
18.0
(12.8 - 24.7)
36.4
(29.3 - 44.1)
29.6
(22.9 - 37.3)
11.8
(7.6 - 17.9)
50.9
(43.2 - 58.6)
16.4
(11.3 - 23.2)
40-49 180 43.1
(35.9 - 50.5)
34.4
(27.6 - 41.8)
32.9
(26.4 - 40.1)
54.0
(46.6 - 61.2)
42.1
(34.9 - 49.7)
21.2
(15.8 - 27.7)
67.2
(60.1 - 73.7)
33.7
(27.2 - 41.0)
50-59 129 57.5
(48.6 - 66.0)
52.1
(43.2 - 60.8)
40.1
(31.9 - 49.0)
65.1
(56.2 - 73.0)
50.1
(41.5 - 58.7)
31.2
(23.9 - 39.7)
83.7
(76.1 - 89.2)
45.4
(36.9 - 54.1)
60-69 94 68.3
(57.8 - 77.3)
60.4
(50.0 - 70.0)
43.1
(33.9 - 52.7)
73.6
(63.2 - 81.9)
56.7
(46.4 - 66.5)
43.7
(33.7 - 54.2)
93.1
(85.5 - 96.8)
54.5
(44.0 - 64.6)
P-value < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < .0001
*JIS-MS based on WC ≥ 94 cm (men) and ≥ 80 cm (women) thresholds. † JIS-MS based on WC ≥ 102 cm (men) and ≥ 88 cm (women) thresholds, i.e. exactly consistent with the R-ATPIII criteria. Data are expressed
as percentages (CI 95%). Non-fasting subjects were eliminated from the analysis.
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9determined by the 94/80 cut-off points (51.7%). Among
the other components, hypertension was the most
commonly abnormal criterion (52.5%) in the study
population.
T h ep r e v a l e n c eo fM Sw a ss i g n i f i c a n t l yh i g h e ri nm e n
than in women as measured by both WC thresholds
(low; 35.5% vs 20.4%; P < 0.0001) and (high; 30.8% vs
18.5%, P< 0.0001), respectively. In terms of odds ratios,
the risk of MS was increased by an age-adjusted factor
2.7 (95%CI: 1.7-3.0) in men for the low WC threshold,
whereas for the high WC threshold, we found OR =
2.3 (95%CI: 1.7-3.0). Likewise, all MS components were
significantly more common in men than in women
except for abdominal obesity as measured by both WC
thresholds. The waist threshold of 102 cm identified
26% of male subjects, while the 94 cm threshold identi-
fied 46% of them. In women, the threshold of 88 cm
identified 35% of positive cases against 58% for the 80
cm threshold.
Regardless of the thresholds used, the MS prevalence
increased remarkably with age in both genders. For the
low WC threshold, when compared to the lowest age
category (18-29 years), the gender-adjusted risk of MS
increased by a factor 2.7 (95%CI: 1.4-5.4), 7.8 (95%CI:
4.1-15), 16 (95%CI: 8.6-31) and 28 (95%CI: 14-54) for
subjects aged 30-39, 40-49, 50-59 and 60-69 years,
respectively. For the high WC threshold, results were
similar; when compared to the lowest age category (18-
29 years), the gender-adjusted risk of MS increased by a
factor 3.3 (95%CI: 1.5-7.2), 8.0 (95%CI: 3.8-17), 18 (95%
CI: 8.5-39) and 31 (95%CI: 14-65) for subjects aged 30-
39, 40-49, 50-59 and 60-69 years, respectively. Similar
patterns were observed for all other components. No
age-gender interaction was found for any of the com-
pared definitions or individual components.
The prevalence of 94/80-defined central obesity was
88% in women and 74% in men aged 60-69 years. In
contrast, the 102/88 thresholds classified 67% of women
and 43% of men as having central obesity in the same
age group.
FRS and JIS definition
After excluding participants with history of CHD, sub-
jects were cross-classified according to their MS status
(MS or not MS) for each definition and to their 10-year
predicted FRS (> 20% or < 20%). Regardless of the defi-
nition used, the proportion of subjects at high 10-year
CHD risk was significantly greater in the MS group
than in the non MS group. When focussing on the WC
thresholds, the proportion of subjects at high CHD risk,
by using the JIS-102/88 criterion, was comparable to
that obtained with the JIS-94/80 definition [9.65% (95%
CI: 6.50 - 12.8) against 8.55% (95%CI: 5.75 - 11.4)],
respectively (Table 2).
JIS-94/80 versus IDF and R-ATPIII definitions
To avoid confusion, only the JIS-94/80 will be used
hereafter, as the JIS-102/88 corresponds exactly to the
R-ATPIII. Figure 1 illustrates the gender- and age- spe-
cific prevalence of MS using the three definitions. Over-
all, JIS-94/80 yielded a higher MS prevalence than IDF
and R-ATPIII in both genders. In men, the IDF and R-
ATPIII prevalence rates were similar (31%), whereas the
JIS-94/80 prevalence of the MS was notably higher
(35.5%). In women, the MS prevalence rates by using
JIS-94/80 (20.4%), IDF (19.3%) and R-ATPIII (18.5%)
were quite comparable. For all age groups, the preva-
lence of MS by using the JIS-94/80 definition was higher
than the IDF and R-ATPIII.
Table 2 The JIS prevalence of metabolic syndrome
according to 10-year predicted risk of coronary heart
disease, using the two waist circumference thresholds
Metabolic
syndrome
Total 10-year CHD risk
(FRS ≥ 20%)
n (%)
(95% CI)
P-value†
JIS-94/80
Yes 386 33 (8.55)
(5.75 - 11.4)
< 0.0001
No 916 7 (0.76)
(0.20 - 1.33)
JIS-102/88*
Yes 342 33 (9.65)
(6.50 - 12.8)
< 0.0001
No 960 7 (0.73)
(0.19 - 1.27)
* JIS-94/80 means the MS as defined by the lower thresholds of the WC
criterion (94 cm for men and 80 cm for women). JIS-102/88 means the MS as
defined by the higher thresholds of WC criterion (102 cm for men and 88 cm
for women). JIS-102/88 corresponds exactly to the R-ATPIII definition. † P
value indicates the comparison between the 10-year CHD risk classes
according to the presence of the MS for each WC threshold.
0
10
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30
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50
60
70
Women Men 18-29 30-39 40-49 50-59 60-69
Gender Age (year)
%
JIS 94/80 IDF R-ATPIII
Figure 1 Gender- and age-specific prevalence of the metabolic
syndrome according to the R-ATPIII, IDF and JIS-94/80
definitions, among the adult residents of Luxembourg,
ORISCAV-LUX study.
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Page 5 of 9Table 3 reports the agreement between the 3 defini-
tions according to gender and age groups. Among all
participants, 97.2% were classified similarly under the
JIS-94/80 and IDF definitions ( = 0.93), likewise when
comparing JIS-94/80 with R-ATPIII (96.7%,  =0 . 9 1 ) .
Lower agreement (93.9%,  = 0.84) was found between
the older definitions (IDF vs R-ATPIII). The degrees of
agreement between the definitions were significantly
h i g h e ri nw o m e nt h a ni nm e n( P< 0.0001). Globally,
agreement between the different age-specific prevalence
rate estimates ranged from 0.69 to 0.96. Despite the
general excellent concordance for the entire population,
differences were noted between age groups.
Discussion
This work innovated by describing for the first time in
Luxembourg the gender and age variation of the preva-
lence of MS and of its components in a representative
sample of presumably healthy 18-69 years old adults,
according to the most recent JIS definition. To evaluate
the impact of different WC cut-off values for diagnosing
MS, the prevalence rates were simultaneously estimated by
using 102/88 and 94/80 thresholds, respectively. In addi-
tion, it aimed to compare and examine the concordance
between the MS definitions currently in operation and
sharing basically the same criteria.
Unsurprisingly, the prevalence of MS was higher by
JIS-94/80 definition (28%) than JIS-102/88 definition
(25%), a difference undoubtedly attributable to WC cut-
offs. Similar findings were observed in some European
countries but not in the United States where the differ-
ence in the MS prevalence, by using the high and low
waist cut-off points, was relatively small because the
prevalence of obesity in USA is higher whichever WC
cut-off points used [16].
T h ee m e r g i n gp r e v a l e n c ed a t ad u r i n gt h ec u r r e n t
decade suggest that MS is quite prevalent worldwide,
especially among older people, with gender-specific
disparities. Consistently,i nt h eO R I S C A V - L U Xs t u d y ,
the MS prevalence rates increased remarkably with age
in both genders, as defined by both WC thresholds.
This effect can be explained largely by age-related rises
of blood pressure and glucose[25]. However, the signif-
icantly higher prevalence of MS and its components in
men is of particular concern, especially for the younger
age groups indicating their potential prolonged expo-
sure to the proatherosclerotic risk factors associated
with the MS.
Paradoxically, although the overall MS prevalence rate
was significantly higher in men than in women, the pre-
valence of abdominal obesity was markedly higher in
women, by using both high and low WC thresholds.
This finding indicates that, in our Europid population,
abdominal obesity was one but not the most important
criterion, particularly in women. Other components
such as elevated blood pressure and dyslipidemia may
account more than or as much as abdominal obesity to
determine the MS diagnosis, challenging therefore the
appropriateness of the IDF criteria.
The suggested WC cut-off points to define the MS
result from experts’ consensus, thus call for validation
by additional clinical and epidemiological prospective
studies. While the WHO identified that a substantially
high risk occurs at WC thresholds of (102/88)[26], the
IDF and EGIR groups suggested lower values (94/80)
[14]
, [27]. Waist circumferences of 102/88 thresholds
were average values corresponding to a BMI of 30 kg/
m
2 in men and women, respectively [28]. Within the
context of the MS, the use of lower cutoff points is ben-
eficial, as it raises the risk level for cardiometabolic dis-
ease among those identified as having the MS[29] and
then indicates the need for early cardiovascular risk
reduction. However, this approach implies a large
impact on preventive strategies and health care
resources. Our findings are important, not only to help
decision-making with respect to the cardiovascular risk
level intervention, but also to argument the future
research work on the MS as a cardiometabolic outcome.
Table 3 Percentage of observed agreements between the
definitions of the metabolic syndrome among the adults
aged 18-69 years residents in Luxembourg, ORISCAV-LUX
study
Agreement* Percent ± SE (Cohen’s kappa coefficient)
JIS-94/80
vs IDF
JIS94/80
vs R-ATPIII
IDF vs R-
ATPIII
JIS-94/80
vs IDF
vs R-ATPIII
Total 97.2 ± 0.46
(0.93)
96.7 ± 0.55
(0.91)
93.9 ± 0.65
(0.84)
93.9 ± 0.65
(0.89)
Gender
Women 98.9 ± 0.38
(0.96)
98.1 ± 0.54
(0.94)
97.0 ± 0.65
(0.90)
97.0 ± 0.65
(0.94)
Men 95.5 ± 0.84
(0.90)
95.4 ± 0.80
(0.89)
90.8 ± 1.12
(0.78)
90.8 ± 1.12
(0.86)
P-value 0.0003 0.007 < 0.0001 < 0.0001
Age
(years)
18-29 98.8 ± 0.90
(0.89)
98.5 ± 0.84
(0.83)
97.3 ± 1.22
(0.69)
97.3 ± 1.22
(0.81)
30-39 99.0 ± 0.58
(0.96)
98.6 ± 0.72
(0.94)
97.6 ± 0.92
(0.90)
97.6 ± 0.92
(0.93)
40-49 97.3 ± 0.87
(0.94)
94.6 ± 1.18
(0.87)
91.9 ± 1.43
(0.80)
91.9 ± 1.43
(0.87)
50-59 94.7 ± 1.40
(0.89)
95.4 ± 1.31
(0.91)
90.1 ± 1.85
(0.80)
90.1 ± 1.85
(0.87)
60-69 94.3 ± 1.72
(0.89)
95.7 ± 1.55
(0.92)
89.9 ± 2.22
(0.81)
89.9 ± 2.22
(0.87)
P-value 0.0002 0.001 < 0.0001 < 0.0001
* Percentage of participants who were classified as either having or not
having the metabolic syndrome under the considered definitions of the
metabolic syndrome.
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tion, the cross-sectional data of ORISCAV-LUX study
were used to compare the proportion of MS cases with
a 10-year predicted CHD risk exceeding 20%, according
to both WC suggested thresholds. Our data suggest that
both WC cut-off values would be appropriate as the
predicted 10-year of CHD risk was similar.
Nevertheless, the established continuous relationship
between WC and clinical outcomes makes the gender-
specific values questionable, especially in women at
menopause with an increase deposition of visceral fat
[17]. Regardless of the thresholds applied, the consistent
gender difference of 14 cm is discriminating, in the
sense that a WC of 80 cm classifies women in a rather
severe category, especially at the age of menopause
where the women girth becomes physiologically larger.
The ORISCAV-LUX findings demonstrated that more
than 75% of women after the age of 50 years were clas-
sified as centrally obese by applying the 80 cm thresh-
old. This issue suggests the need to reconsider the
current IDF waist circumference recommendations,
notably for the female elderly groups.
By comparing the three last definitions, the prevalence
of JIS-94/80 MS was higher than IDF and R-ATPIII MS.
This pattern of distribution was more prominent for
men than for women. Regardless of the definition used,
the prevalence of the MS increased across age groups.
Concerning the agreement between definitions,
although the IDF placed more emphasis on central obe-
sity in the causation of the MS, remarkable levels of
agreement were found with the JIS ( = 0.93) and good
ones with the R-ATPIII ( = 0.84), indicating that the
requirement of abdominal obesity did not induce impor-
tant discrepancies in the prevalence or the classification
of the MS, but rather the WC cut-off points. Similar
results were found in a large Chinese population [30]
and other Caucasian populations[31]
, [32].
The use of different definitions has an impact on the
estimated prevalence and confuses the interpretation of
epidemiological studies[31]
, [33]
, [34]. A marked gender
and American-European population’sd i f f e r e n c ew a s
observed[35]. In an attempt to harmonize the MS defi-
nition by comparing the R-ATPIII and the IDF criteria
in American and German populations, Assmann et al.
presumed that the observed prevalence discrepancy and
particularly the gender-specific disagreement, by using
the 2 different criteria, depend on the population char-
acteristics, since a greater portion of German cohort
population had lower WC measurements and were gen-
erally leaner than Americans[35]. Despite the intensive
efforts of scientific societies to harmonize the criteria to
define the MS, a key consideration remains controversial
for WC cutoff points in the Europid population. Given
the “almost perfect” level of agreement between the
J I S -a n dR - A T P I I I - d e f i n e dM S(  = 0.91), our results
indicate that the two suggested cut-off points do not
affect the prevalence estimates of the MS. In addition,
the 10-year predicted CHD risk by FRS was similar for
both thresholds-based definitions.
In general, a good agreement was found between the
three definitions ( = 0.89). This high degree of concor-
dance and significant identification of a large number of
participants as having the MS were not surprising, con-
sidering the fact that the three definitions use the same 5
components and that 4 out of five are defined identically
[36]. In addition, despite the differences in their con-
structs, the concordance between the studied definitions
was optimal in women as compared to men. In other
words, the same individuals are essentially identified as
having MS by using any construct criteria. In the most
recent JIS definition, the IDF agreed to consider abdom-
inal obesity as one of the 5 criteria and not deemed as a
prerequisite element to diagnose the MS [16]. This har-
monization is a step forward for a universal harmoniza-
tion and allows a relevant international comparison.
The cross-sectional design of the ORISCAV-LUX
study limits the possibility to determine which criteria
better predicts adverse cardiovascular outcomes, such as
the incidence of coronary events and thus precludes
causal inferences. However, several strong points charac-
terize the study. First, it is based on recent nationwide,
population-based, representative sample of Luxembourg
adult residents, from whom extensive direct measure-
ments were obtained. A detailed study of non partici-
pants showed that the demographic and clinical
characteristics of the ORISCAV-LUX participants were
comparable with those of the non-participants[21]. The
data were weighted to provide population-representative
prevalence estimates.
In line with the 2009 JIS recommendation, a novel
aspect of this study was to assess the MS according to
the most recent definition together with the lower and
higher criteria for Europids. Furthermore, the predomi-
nantly white homogenous nature of the sample (94.2%
Europid) ensured the control over ethnicity factor,
hence allowed generalizing the results.
Conclusion
In conclusion, regardless of the MS definition, this
representative sample of the Luxembourg Europid adult
population demonstrated a high prevalence of MS,
although using the IDF-defined abdominal obesity cri-
terion (94/80) inflated the prevalence estimate, notably
among elderly groups. This fact underscores the impor-
tance of promoting healthy lifestyles, such as proper
nutrition, weight management, and adequate physical
activity among the apparently healthy adults to fight
against this emerging cardiometabolic disorder.
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Page 7 of 9Our data contribute to build evidence regarding the
definitive construct of the MS, to ascertain that both
WC thresholds would be appropriate to define the pre-
valence of the MS in the Europid population, and to
stress the need for revising the guidelines about the
waist circumference cut-off points, particularly in
women after menopause. These perspectives could be
evidently accomplished by epidemiological longitudinal
data.
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